Humacyte (HUMA) Expected to Release Earnings on Tuesday

Humacyte (NASDAQ:HUMA) is projected to release its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $0.77 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. On average, analysts expect Humacyte to post ($0.40) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Humacyte Stock Performance

Shares of HUMA stock opened at $0.44 on Wednesday. The stock’s 50-day moving average is $0.51 and its two-hundred day moving average is $0.80. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. Humacyte has a 1 year low of $0.34 and a 1 year high of $1.56. The firm has a market cap of $122.37 million, a price-to-earnings ratio of -0.90 and a beta of 2.64.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, October 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. Barclays upgraded Humacyte to a “hold” rating in a research note on Wednesday, October 7th. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Benchmark lowered their target price on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a research report on Thursday, August 13th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.96.

About Humacyte

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.